Uri A Liberman

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. ncbi request reprint Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence
    Uri A Liberman
    Department of Physiology and Pharmacology, Sackler School of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Israel
    Drugs Aging 23:289-98. 2006
  2. ncbi request reprint Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials
    U A Liberman
    Felsenstein Medical Research Center, Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Int J Clin Pract 60:1394-400. 2006
  3. ncbi request reprint Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Osteoporos Int 16:468-74. 2005
  4. ncbi request reprint Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study
    Ronald Emkey
    Radiant Research, Wyomissing, Pennsylvania 19610, USA
    Arthritis Rheum 48:1102-8. 2003
  5. ncbi request reprint Ten years' experience with alendronate for osteoporosis in postmenopausal women
    Henry G Bone
    Michigan Bone and Mineral Clinic, Detroit 48236, USA
    N Engl J Med 350:1189-99. 2004

Detail Information

Publications5

  1. ncbi request reprint Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence
    Uri A Liberman
    Department of Physiology and Pharmacology, Sackler School of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Israel
    Drugs Aging 23:289-98. 2006
    ..For other dosing regimens, additional data are needed to evaluate their long-term safety...
  2. ncbi request reprint Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials
    U A Liberman
    Felsenstein Medical Research Center, Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Int J Clin Pract 60:1394-400. 2006
    ..There is insufficient and/or inconsistent evidence of an effect on these fractures for IBN, calcitonin and raloxifene...
  3. ncbi request reprint Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Osteoporos Int 16:468-74. 2005
    ..The overall reduction is consistent among different patient populations...
  4. ncbi request reprint Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study
    Ronald Emkey
    Radiant Research, Wyomissing, Pennsylvania 19610, USA
    Arthritis Rheum 48:1102-8. 2003
    ..To evaluate the effects of discontinuing or continuing alendronate (ALN) therapy on bone mineral density (BMD) after patients on a long-term regimen of glucocorticoids (GCs) completed a 1-year treatment period with ALN...
  5. ncbi request reprint Ten years' experience with alendronate for osteoporosis in postmenopausal women
    Henry G Bone
    Michigan Bone and Mineral Clinic, Detroit 48236, USA
    N Engl J Med 350:1189-99. 2004
    ..Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years...